Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?. (October 2015)

• Record Type: Journal Article
• Authors: Mittal, Mayank; Aggarwal, Kul; Littrell, Rachel L.; Agrawal, Harsh; Alpert, Martin A.
• Is Part Of: Hemodialysis international. Volume 19(2015)Supplement 3
• Page Start: S40
• Page End: S50
• Publication Date: 2015-10
• Subjects: Cardiovascular disease -- hemodialysis -- hypertension -- dyslipidemia -- anti‐platelet therapy -- anticoagulation; Hemodialysis -- Periodicals; Renal Dialysis -- Periodicals; Renal Dialysis -- Congresses; Hemodialysis, Home -- Congresses; 617.461059
• DOI: 10.1111/hdi.12352
• Languages: English
• ISSNs: 1492-7535

Abstract

Abstract: Cardiovascular disease (CVD) occurs commonly in patients with chronic kidney disease (CKD) including those treated with hemodialysis (HD), and is associated with poor outcomes in this population. Pharmacologic management of hypertension, dyslipidemia, acute and chronic coronary artery disease, and atrial fibrillation in the general population is supported by the results of high‐quality, randomized, controlled clinical trials. Pharmacotherapy of these disorders in the general population is effective in improving clinical outcomes. In contrast, information concerning the effect of pharmacotherapy on mortality and cardiovascular outcomes in patients with CKD, and particularly in HD patients, is limited. Available data suggest that, in general, pharmacotherapy of hypertension and dyslipidemia, anti‐platelet therapy of CVD, and anticoagulant therapy in patients with atrial fibrillation are less effective in HD patients than in the general population or even in patients with early stage of CKD.